Ray, JC;
Kapoor, M;
Stark, RJ;
Wang, S-J;
Bendtsen, L;
Matharu, M;
Hutton, EJ;
(2021)
Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects.
Journal of Neurology, Neurosurgery & Psychiatry
10.1136/jnnp-2020-324674.
(In press).
Preview |
Text
Matharu_CGRP manuscript marked.pdf - Accepted Version Download (351kB) | Preview |
Abstract
Migraine is the second largest cause of years lost to disability globally among all diseases, with a worldwide prevalence over 1 billion. Despite the global burden of migraine, few classes of therapeutics have been specifically developed to combat migraine. After 30 years of translational research, calcitonin gene-related peptide (CGRP) inhibitors have emerged as a promising new tool in the prevention of migraine. Like all new therapeutics; however, we have limited real-world experience and CGRP has several known systemic actions that warrant consideration. This article provides a narrative review of the evidence for CGRP antagonists and summarises the known and potential side effects that should be considered.
Archive Staff Only
 |
View Item |
